EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool

Yue Ma, Yuting Pan, Yue Li, Huafang Guan, Guanghai Dai

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05771-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Yue Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, 100853, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Biliary Tract Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The emergence of immune checkpoint inhibitors (ICIs) has enhanced survival outcomes for certain patients with advanced biliary tract carcinoma (BTC). Pinpointing those who would benefit most from immunotherapy remains elusive. We investigated the predictive value of the modified Gustave Roussy Immune Score (mGRIm-s) in BTC patients treated with ICIs.

Methods

Data from 110 patients at Chinese People's Liberation Army General Hospital, spanning September 2015 to April 2021, were analyzed. The median follow-up duration was 38.7 months as of December 2023. Risk factors included low albumin, high lactate dehydrogenase, and an elevated neutrophil–lymphocyte ratio. Patients were stratified into low (patients with no risk factors) and high (patients with at least one risk factor) mGRIm-s groups based on these factors.

Results

Survival outcomes post-immunotherapy favored the low mGRIm-s group, with significantly improved progression-free survival (PFS) and overall survival (OS) (8.50 months vs. 3.70 months and 21.60 months vs. 8.00 months). COX regression confirmed an elevated risk in the high mGRIm-s group. Subgroup analysis highlighted a notable survival advantage for low mGRIm-s patients receiving first-line immunotherapy.

Conclusions

This study underscores mGRIm-s's potential in predicting immunotherapy response in BTC, paving the way for more targeted approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsBiliary Tract NeoplasmsHumansMaleFemaleMiddle AgedPrognosisAgedAdultRetrospective StudiesImmunotherapyAged, 80 and over

Stichwörter der Autor:innen

Advanced bile tract carcinomaImmunotherapyPrognosisThe modified -Gustave Roussy Immune Score

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical School of Chinese PLA, Beijing, 100853, China.
  • Department of Medical Oncology, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
  • Department of Medical Oncology, the Fifth Medical Centre, Chinese PLA General Hospital, Beijing, 100039, China.
  • Yingtan City People's Hospital, Yingtan, 335000, China.
  • Medical School of Chinese PLA, Beijing, 100853, China. daiguanghai@301hospital.com.cn.
  • Department of Medical Oncology, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China. daiguanghai@301hospital.com.cn.

Zitieren

APA

Ma, Y., Pan, Y., Li, Y., Guan, H., & Dai, G. (2024). Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05771-w

Vancouver

Ma Y, Pan Y, Li Y, Guan H, Dai G. Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05771-w

BibTeX
@article{Ma2024,
  author = {Ma, Yue and Pan, Yuting and Li, Yue and Guan, Huafang and Dai, Guanghai},
  title = {Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05771-w}
}
Kostenlos starten →